In a murine ovarian cancer model, the administration of decitabine in combination with anti-CTLA-4 therapy led to increased efficacy and prolonged CD8+ tumor-infiltrating lymphocytes (TILs) response (108). The gene discussed is CD8A; the disease is neoplasm.